 S deÔ¨Åciencies),
factor V Leiden (resulting in activated protein C resistance),
prothrombin G20210A, plasminogen activator inhibitor
type 1 mutations, hyperhomocysteinemia, antiphospholipid
antibodies (anticardiolipin and lupus anticoagulant), and
cryoglobulins and cryoagglutinins.
Guideline 3.7: Arterial